Background: Although the average age of lung cancer patients is increasing, many elderly patients remain undertreated, mainly because of the fear of higher treatment toxicity in this category of patients. We conducted a study to evaluate the efficacy and tolerability of a combination therapy with carboplatin (C) and etoposide phosphate (EP) in elderly patients with Small-Cell Lung Cancer (SCLC).
Introduction
The elderly population is growing in industrialised countries and, in fact, elderly people account for an increasing proportion of patients with cancer. The incidence of lung cancer increases with age and the number of elderly patients with lung cancer is consequently going to increase in the next few decades [1] .
Currently, the median age of newly diagnosed smallcell lung cancer (SCLC) patients is 63 years and patients more than 70 years old account for 25% [2, 3] . Unfortunately, in most published clinical trials, this population is excluded or under-represented due to restrictive inclusion criteria concerning age limit, comorbidity, renal and hepatic functions. Oncologists may also consider that elderly patients are less tolerant of aggressive therapy, and, even if there is no age limit for inclusion in a trial, physicians are sometime reluctant to include older patients. Effectively, some authors report a greater bone marrow toxicity with early death in 20% of cases [4] , although others have not found any difference [5] . Thus, the elderly often receive suboptimal treatment by radiotherapy or low-dose chemotherapy [3, 6] and, consequently, the real prognostic value of age is difficult to estimate. Chemotherapy is the cornerstone of the treatment of SCLC. The most commonly used drugs are cyclophosphamide, doxorubicin, vincristine, etoposide and cisplatin. The cisplatin and etoposide combination is currently widely used and considered as standard therapy in most countries, either associated or not associated with other drugs.
However, age-related renal dysfunction and the hyperhydration needed can make the use of cisplatin problematic. Moreover, gastro-intestinal toxicity is often unacceptable for the elderly. Renal, gastro-intestinal and neurological side effects are less marked with carboplatin, and the Calvert formula allows individual adaptation of the doses [7] .
The efficacy of carboplatin as monotherapy [8] or in combination with etoposide [9] [10] [11] has been demonstrated in the treatment of SCLC patients. Kosmidis et al. [12] , assessing comparatively in SCLC patients the efficacy and safety of cisplatin-etoposide (EP) and carboplatin/etoposide (CP) combinations, reported that both treatments proved to be effective but leukopenia, neutropenic infections, nausea, vomiting, nephrotoxicity and neurotoxicity were more frequent and/or severe in the EP group.
Monotherapy with etoposide has also been proposed in elderly patients [2, 13] . However, data from randomised studies have shown poorer results in the groups of patients treated by oral etoposide alone in comparison to multidrug regimen therapy [14, 15] , and most authors recommend combination therapy as standard treatment for all elderly patients with SCLC able to receive it [16, 17] .
Although oral etoposide may be more convenient, the inter-and intra-individual variability of its bioavailability and the decrease in gastro-intestinal absorption in the elderly make the intravenous route preferable. Etoposide phosphate is a water-soluble pro-drug of etoposide [18] . Due to its good solubility and stability, it can be administered intravenously at high concentrations (up to 20 mg/1), and short infusions of 5-15 minutes, instead of 30-45 minutes for etoposide, are possible [19] . Moreover, the absence of organic solvents minimizes the risk of hypotension in comparison with i.v. etoposide. The bioequivalence of the two products [20] allows the replacement of oral etoposide by intravenous etoposide phosphate in order to avoid the pharmacokinetic variations associated with oral administration and to shorten administration by delivery in a small volume.
\'
We conducted a multicentric non-comparative phase | II study in order to assess the efficacy and safety of the carboplatin-etoposide phosphate combination in patients older than 70 years with SCLC.
Patients and methods

Eligibility criteria
Patients older than 70 years with histologically confirmed, limited disease unsuited for radiotherapy, or extensive-stage SCLC were eligible. All patients were required to have measurable disease at least at one site. Other requirements were performance status (PS) $ 2, adequate haematologicul parameters (granulocyte count ^ 2.0 x 10 9 /l, platelet count ^ 150 x IO 9 /I) and satisfactory renal function (serum creatinine level < 2 x upper limit of the normal laboratory value). The main non-inclusion criteria were brain metastasis with neurological symptoms, unstable or uncontrolled heart disease, uncontrolled infection, history of malignancies and life-expectancy <3 months. Written informed consent was to be obtained from all patients.
Treatment delivery
Carboplatin, diluted before use in 250 ml of DW5. was administered on day I. The dose was calculated according to the formula defined by Calvert (AUC x (glomerular filtration rate + 25)), for a target AUC value of 5 mg/ml/min. Etoposide phosphate at a dose of 100 mg/m 2 . was administered at day I, D2 and D3 by a 5-15 minute infusion, after dilution in 100 ml of DW5 to give a final concentration of 1 5-2 mg/ml.
Haematopoietic growth factors were allowed as prophylactic or curative treatment only ifgrade 4 neutropenia > 7 days occurred.
Cycles of chemotherapy were repeated at four-week intervals if the patient had recovered from all toxicities related to the previous cycle. Drug dosages were modified according to toxicities as follows: in the case of grade 4 neutropenia > 7 days or febrile neutropenia, etoposide phosphate dose was reduced by 25%, and target AUC value reduced to 4 for carboplatin. In the case of grade 4 thrombocytopenia. the AUC value of carboplatin was also reduced to 4. If on day 28 leucocyte count was <1.5 x 10 9 /l and/or platelet count was < 100 x 1O 9 /1. chemotherapy was to be delayed for one week. If the creatinine level was > 2 x upper limit of the normal value, carboplatin was stopped. In the event of grade 3-4 allergic reaction, etoposide was to be stopped. In the case of grade 2 allergic reaction, patients were given corticosteroid medication and monitored during the following infusions of etoposide.
All patients had to be given at least two cycles of chemotherapy, unless progression of disease, excessive toxicity or rapid clinical deterioration occurred. Treatment was continued for a maximum of six cycles, provided that progression did not occur. Toxicity was graded according to the World Health Organisation [21] toxicity scale.
Patients were re-evaluated for assessment of responses after two cycles, then at completion of chemotherapy or at progression. Responses, determined on the basis of the best responses observed at restaging, were evaluated according to the WHO criteria.
Survival time was calculated from the start of the treatment until death or the last follow-up evaluation (1-7-2000) .
Results
Patient characteristics
Thirty-eight previously untreated elderly patients with SCLC were included in the study by ten French centres between December 1997 and June 1999. Median age was 75 years (range 70-88 years).Twenty patients were older than 75 years and seven more than 80 years. At the time of diagnosis, the majority of patients (68%) had disseminated disease.
The main characteristics of the eligible patients are listed in Table 1 . During this period, 27 other previously untreated patients older than 70 years (median age: 74 years, range 70-91 years) were diagnosed with SCLC in the participating centres but not enrolled in this protocol due to the presence of an exclusion criterion, mainly a very bad performance status, a history of another cancer or an evolutive heart disease.
Treatment delivery
Thirty-eight patients received a total of 162 cycles of etoposide phosphate and carboplatin. The number of cycles per patient ranged from one to six (Table 2) . Seven patients died before the second cycle. Eighteen patients (47%) received the six scheduled cycles.
The reason for treatment discontinuation was death for 11 patients. The other reasons included disease progression (n -7), refusal of the patient to go on with the treatment (i\ -1, stable disease at first evaluation) and episodes of pulmonary oedema estimated to be treatment-related (n = 1, partial response).
It is important to point out that all 162 cycles were performed at the scheduled time, no cycles being delayed due to the non-recovery of toxicities related to the previous cycle. 
Response rate and survival
The overall objective response rate was 60.5% (2 complete responses and 21 partial responses). Five patients had stable disease, two progressive disease (Table 3 ). Considering only the 30 patients evaluable for response (one patient died just after the second cycle, before evaluation) the objective response rate was 76.7%.
The response rate was similar irrespective of the disease stage. Eighteen patients received the six scheduled cycles (five with limited disease, thirteen with disseminated disease). After these six cycles, there were two complete responses (two patients with disseminated disease), thirteen partial responses and three cases of progressive disease. Overall, the median survival was 237 days (range 2-929+ days). The median survival time ( Figure 1 ) was 220 days for patients with disseminated disease and 257 days for those with limited disease. The one-year probability of survival was 26.3% (10 of 38 patients).
Safety
Death was the reason for cessation of the treatment for eleven patients (29%), of whom three had a partial response at the first evaluation and eight were not evaluable. The reasons for early death are summarized in Table 4 . Seven patients died before receiving the second cycle, two deaths being clearly related to treatment toxicity: one tumor lysis with renal failure and one septic shock secondary to Pseudomonas aeruginusa bacteriaemia, during the course of a grade 4 neutropenia. Two patients died of cardiac failure (one myocardial infarction and one cardiogenic shock due to rhythm disorders), one patient died of pulmonary embolism and one of massive haemoptysis. The cause of sudden death was not elucidated for one patient (normal clinical examination the day before). Three patients were withdrawn from the study because of treatment-related adverse events: two, previously mentioned, died before the second cycle. The other, with a previous history of cardiopathy, experienced repetitive acute pulmonary oedemas at each cycle, which were considered to be treatment-related. However, repeated episodes of car- One patient experienced a grade 1 cutaneous rash during three of the four cycles he received. Grade 3 alopecia occurred in six of the eighteen patients completing the six scheduled cycles. It is noteworthy that no renal toxicity (apart from the renal failure due to tumour lysis after one cycle) or liver toxicity was observed during this study.
Effect of age on the main parameters
Although the total number of patients was too small to permit valid comparison of the main parameters according to age, the possible existence of trends was explored, stratifying the patient population into the age groups 70-74 years, 75-80 years and older than 80 years. Table 5 indicates the main results. It is noticeable that in the oldest group, four of the seven patients received the six scheduled cycles, and that an objective response was observed in six patients. The mean survival may appear shorter in the oldest group, but the number of patients was very small and three of them died prematurely. The deaths were imputable to a myocardial infarction after the first cycle, an acute respiratory distress after the second cycle and a stroke occurring after the fourth cycle. The haematological toxicity did not seem to increase with age.
Discussion
Current treatment of SCLC consists of combination chemotherapy with or without mediastinal irradiation. In our study, patients with limited disease were included only if the physician thought they were not suitable for radiotherapy. A review of the literature suggests that many physicians do not feel that the potential benefits outweigh the predictable side-effects of chemotherapy in older patients [3, 22] . Moreover, older patients are often excluded from clinical trials with standard chemotherapy based on platinum, anthracyclines and podophyllotoxins because of the renal, cardiac and haematopoietic toxicities, and it is likely that many older patients with SCLC are not treated or are undertreated because they are considered to be less tolerant of aggressive chemotherapy [23] . Concomitant chronic disease may also dissuade oncologists from offering standard chemotherapy. Some authors have shown that patients older than 70 years with SCLC have only half the likelihood of receiving chemotherapy compared with younger patients [3] . However, it is not clear whether age is an important prognostic factor with respect to response to chemotherapy [3, 23] .
In order to design potentially less toxic therapeutic regimens for older patients, we assessed the safety and efficacy of a combination of etoposide phosphate and carboplatin. The considerations promoting the use of such a combination in an elderly population included an expected decrease in toxicity without loss of efficacy and an acceptable implementation in geriatric patients.
The results of our study indicated the feasibility of treating elderly patients with combined etoposide phosphate carboplatin chemotherapy, 68% of the patients receiving at least four cycles and 47% receiving the scheduled maximum of six cycles. The objective response rate was 60.5% (76.7% considering only the evaluable patients) and the median time of survival was 7.9 months. The study population was too small to permit a distinction between patients with limited or disseminated disease, and consequently to draw definitive conclusions. These results may appear to be somewhat poorer than others previously published, using different modes of chemotherapy. However, a quarter of these patients survived for more than one year and most of them would probably not have been eligible for randomised trials because of age or comorbidities.
Overall, the tolerability of the treatment was rather good, and patients could receive the full scheduled dose on time at each cycle. The most frequent toxicity was grade 3-4 neutropenia, which was transient and without clinically deleterious consequences except in one patient. The gastro-intestinal, hepatic and renal safety was very good. No patient had to be rehospitalised due to the occurrence of a treatment-related adverse event.
Unfortunately, a relatively high proportion of the enrolled patients died shortly after the start of this trial (11 patients, mean age 75 years). Seven of them died after the first cycle and two more before the third cycle, although the inclusion criteria stipulated a life expectancy > 3 months. Except for two patients, the deaths did not seem to be related to the treatment. For the three patients dying of acute respiratory distress or massive haemoptysis, disease progression may have been invoked. One patient, with a history of deep vein thrombosis, died of pulmonary embolism. Four patients died from cardiovascular disease (two of myocardial infarction, one of rhythm disorder and one of a stroke). With reference to the myocardial infarctions and cardiac failure due to arrhythmia, we cannot totally rule out toxicity due to chemotherapy since vasospastic angina [24] and myocardial infarction have been reported after infusion of etoposide [25] . All of these patients had a history of cardiovascular disease, as had 16 other patients.
Comorbidities are very frequent in older cancer patients, and can undoubtedly have a great impact on survival. It has been shown that comorbidity and functional status, the latter being the only parameter scored in most protocols, are poorly correlated in older patients [26] . In most geriatric studies, comorbidity and functional status were independent predictors for outcomes such as survival and hospitalisation rates, and both should probably be assessed in older cancer patients. However, comorbidity rating is very sensitive to definition, and marked differences in scoring may be observed between indices [26] .
A question arising from this high early mortality rate, which contrasts with the generally tolerable safety of the chemotherapy in most patients, is the possibility of an exacerbatory effect of the treatment on comorbidities, particularly cardiovascular. An abrupt decline of the survival curve after the first few weeks of treatment by etoposide has already been observed in several trials [27] .
Nevertheless, even if comorbidity explains in part the exclusion of patients from a protocol or the use of less aggressive therapy, it is not known whether or not these therapeutic attitudes are really justified. Including older patients with comorbidities appears to us essential, since they represent a large proportion of lung cancer patients. In the study of Dajczman et al., 75% of SCLC patients older than 70 years had comorbidities, and only 1 of 81 of these patients was enrolled in a study protocol. In a survey made by Carney, only 26% of more than 300 patients were considered candidates for combined modality therapy, the main exclusion criteria including age > 65 years, extensive disease and PS = 3.
In our studies, the high rate of early death probably reflects the poor condition of these relatively unselected patients in terms of comorbidities and also the inherent mortality of this age group. However, despite the early death rate, the one-year probability of survival was 26%, within the range of what is generally observed in the extensive disease stage.
Conclusion
The elderly represent an important proportion of patients with SCLC, but optimal treatment of the disease in this age group remains uncertain and controversial. The results of this study showed that the two-drug regimen of carboplatin and etoposide phosphate is feasible in most elderly patients with a relatively good safety profile and is capable of achieving quite a good overall response rate and survival, although a potential negative impact of chemotherapy on comorbidities cannot be exluded.
Overall, the results suggest that patients even older than 70 years may benefit from full treatment, and therefore consideration should be given to offering active treatment to most patients with SCLC, regardless of age and comorbidities, although the best chemotherapy combination remains to be determined. There is still room for phase II trials in this group of older elderly patients testing regimen with fewer haematologic toxicities and necessitating a shorter duration of treatment.
